Loading...
Loading...
ANGN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 10.8M |
| Operating I/L | -10.8M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.2M |
| Pretax | -10.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.7M |
Angion Biomedica Corp. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate, ANG-3070, is an oral tyrosine kinase receptor inhibitor designed to treat fibrotic diseases, particularly in the kidney and lung. Additionally, Angion Biomedica Corp. develops ANG-3777, a hepatocyte growth factor mimetic for acute organ injuries, ROCK2 inhibitors programs for fibrotic diseases, and a CYP11B2 inhibitor program.
